Differential requirement for CD28 and CD80/86 pathways of costimulation in the long-term control of murine gammaherpesvirus-68  by Lyon, Ashley B. & Sarawar, Sally R.
06) 50–56
www.elsevier.com/locate/yviroVirology 356 (20Differential requirement for CD28 and CD80/86 pathways of costimulation
in the long-term control of murine gammaherpesvirus-68
Ashley B. Lyon, Sally R. Sarawar ⁎
Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121-1122, USA
Received 30 March 2006; returned to author for revision 8 May 2006; accepted 7 June 2006
Available online 24 August 2006Abstract
The costimulatory molecules CD80 and CD86 (B7-1 and B7-2) are upregulated on mature antigen-presenting cells and interact with positive
and negative regulators of CD8 T cell function, CD28 and CD152 (CTLA4) respectively. In this study, we examined the role of CD80 and CD86
in the immune response to murine gammaherpesvirus-68 (MHV-68) using CD80/86−/− mice. As we had previously shown that CD28 (the only
known activating receptor for CD80 and 86) is not essential for long-term control of MHV-68, we predicted that CD80 and 86 would also be
dispensable for an effective response to this virus. However, surprisingly, we observed that CD80/86−/− mice failed to maintain effective long-
term control of MHV-68 and showed viral reactivation in the lungs. We did not observe viral reactivation in mice deficient in either CD80 or
CD86 alone, indicating that these molecules play overlapping roles in the long-term control of MHV-68. Antiviral antibody responses were
dramatically reduced in CD80/86−/− mice, while CD8 T cell expansion and recruitment to the lungs were not significantly affected. The
unexpected disparity in the requirement for CD28 and CD80/86 in the response to MHV-68 suggests that CD28 is not the only positive regulatory
receptor for CD80/86.
© 2006 Elsevier Inc. All rights reserved.Keywords: CD80; CD86; CD28; Murine gammaherpesvirus; Lung; CD8 T cell; Antiviral antibodyIntroduction
Murine gammaherpesvirus-68 (MHV-68) is a naturally
occurring rodent pathogen (Blaskovic et al., 1980) which is
closely related to Epstein Barr virus (EBV) and the Kaposi's
sarcoma-associated human herpesvirus 8 (KSHV, HHV-8)
(Efstathiou et al., 1990a, 1990b; Virgin et al., 1997).
Intranasal (i.n.) administration of MHV-68 results in acute
productive infection of lung alveolar epithelial cells and a
latent infection in several cell types including B lymphocytes,
dendritic cells, epithelia and macrophages (Flano et al., 2000;
Stewart et al., 1998; Sunil-Chandra et al., 1992a, 1992b; Weck
et al., 1999). Infectious virus is cleared from the lungs
approximately 10 days after infection by a T-cell-mediated
process (Ehtisham et al., 1993; Topham et al., 2001). The
antibody response develops several weeks after infection
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dependent mechanisms (Kim et al., 2002; Stewart et al.,
1998). While CD4 T cells are not essential for primary control
of lytic MHV-68, they are required for long-term control and
the virus reactivates in the lungs of CD4 T-cell-deficient mice
(Cardin et al., 1996).
As predicted by the two-signal hypothesis, both TCR-
mediated and costimulatory signals are important in T cell
activation during MHV-68 infection. Thus CD40-CD40L
interactions appear to be critical for T-cell-mediated control of
MHV-68 (Brooks et al., 1999; Lee et al., 2002; Sarawar et al.,
2001). CD40 ligation induces upregulation of CD80 and CD86
on antigen-presenting cells (Cella et al., 1996). These molecules
interact with CD28 resulting in T cell activation and CTLA4
(cytotoxic T lymphocyte antigen-4) resulting in inhibition of T
cell function (reviewed in Chambers et al., 2001; Sharpe and
Freeman, 2002). However, surprisingly, neither CD28 nor its
downstream signaling molecule PKCθ appears to be essential
for the T cell activation events required for either acute or long-
term control of MHV-68 (Giannoni et al., 2005; Kim et al.,
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CD80/86 in the immune response to MHV-68 and, interestingly,
discovered a CD28-independent role for these molecules in the
long-term control of the virus.
Results
Differential requirement for CD80/86 and CD28 in the
long-term control of MHV-68
Previous studies have shown that CD28−/− mice maintain
effective long-term control of MHV-68, while mice lacking
CD4 T cells or CD40 initially control the virus but later show
viral reactivation in the lungs (Cardin et al., 1996; Kim et al.,
2002; Lee et al., 2002). As CD28 is the only known activating
receptor for CD80 and 86, we anticipated that long-term
control of MHV-68 would also be independent of CD80 and
86. To test this assumption, wild-type and CD80/86−/−
(double-deficient) mice were infected intranasally with
MHV-68 and virus titers were determined in the lungs at
days 16 and 50 after infection. As expected, no replicating
virus was detected in the lungs of CD80/86−/− mice at day 16
after infection (Fig. 1), showing that initial control of lytic
virus was effective. Latent virus was also assessed in the
spleens of wild-type and CD80/86−/− mice using an infectious
center assay at day 16 after infection, which is when the peak
number of latently-infected cells is observed in this viral
model. The frequency of infectious centers in splenocytes from
CD80/86−/− mice (856±196, mean±standard error) was not
significantly different from that in wild-type mice (526±73,
mean±standard error).
However, surprisingly, CD80/86−/− showed significant viral
reactivation in the lungs at day 50 after infection (Fig. 1),
whereas no virus was detected in the lungs of wild-type (WT) or
CD28−/−mice, confirming our earlier studies (Lee et al., 2002).
Comparison with MHC Class II−/− mice suggested that the
levels of replicating virus were slightly lower in the lungs ofFig. 1. Differential requirement for CD80/86 and CD28 in the long-term control of MH
days 16 or 50 after infection, lungs were harvested and virus titers were determined
tissue from individual mice and are combined from 2 independent experiments. Horizo
is 10 PFU/0.1 g of lung tissue.CD80/86−/− than in those of Class II−/− mice (Fig. 1). Thus,
these data reveal a differential requirement for CD80/86 and
CD28 in the long-term control of MHV-68.
CD80 and CD86 play overlapping roles in the long-term
control MHV-68
Our next question was whether CD80 and 86 played
distinct or overlapping roles in the long-term control of
MHV-68. To address this question, we compared the long-
term control of MHV-68 in mice that were deficient in either
CD80 or CD86 or in both molecules. We also compared peak
virus titers in the lungs of wild type, CD80−/−, CD86−/−
and CD80/86−/− mice at day 7 post-infection. Groups of
wild type, CD80−/−, CD86−/− or CD80/86−/− mice were
infected intranasally with MHV-68 and lung virus titers were
determined 7 or 50 days later. Although, on average, lung
virus titers at day 7 post-infection appeared to be slightly
higher for mice lacking CD80 or 86 than for wild-type mice
(Fig. 2), the difference was not statistically significant. The
results at day 50 post-infection demonstrated that neither
CD80−/− or CD86−/− mice showed reactivation of MHV-68
in the lungs (Fig. 2), whereas replicating virus was detected
in the lungs of CD80/86−/− mice. Thus CD80 and CD86
appear to play overlapping roles in the long-term control of
MHV-68.
Unaltered lymphocyte numbers and subset distribution in the
lungs and spleen of CD80/86−/− mice
Wild-type mice infected with MHV-68 develop splenome-
galy and an inflammatory infiltrate in the lungs, comprising
mainly T lymphocytes and monocyte/macrophages. To
determine whether deficiency of both CD80 and 86 affects
the lymphocyte expansion and recruitment that is necessary
for these effects, cell numbers and the distribution of
lymphocyte subsets were evaluated in the lungs and spleensV-68. Groups of 3–5 mice were infected intranasally with 105 PFUMHV-68. At
in lung homogenates by plaque assay. Data are expressed as PFU/0.1 g of lung
ntal bars represent the mean titer for each group. The detection limit of this assay
Fig. 2. CD80 and CD86 play overlapping roles in the long-term control MHV-68. Groups of 3–4 wild-type (WT), CD80−/−, CD86−/− or CD80/86−/− mice were
infected with MHV-68 and lung virus titers were determined at days 7 or 50 after infection as described in the legend to Fig. 1.
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parameters were examined at day 16, when the inflammatory
infiltrate and splenomegaly are maximal and at day 50, when
the number of inflammatory cells in the lung and splenocyte
cell numbers have diminished considerably. Both wild-type
and CD80/86−/− mice developed splenomegaly and inflam-
matory infiltrates in the lungs. There was no significant
difference in the cell numbers in the spleen or bronchoalveolar
lavage (BAL) of wild-type and CD80/86−/− mice at either day
16 or day 50 (Fig. 3). Similarly there was no significant
difference in lymphocyte subset distribution in the spleen or
BAL between the two groups of mice at either time-point (Fig.
4). These data suggest that CD80 and 86 are not essential for the
lymphocyte activation events that are required for the induction
of splenomegaly or for lymphocyte trafficking to the lung in
response to MHV-68 infection.Fig. 3. Cell numbers in the bronchoalveolar lavage (BAL) and spleens of MHV-68-in
determined at day 16 or 50 after infection with MHV-68. Single cell suspensions w
determined by Trypan Blue exclusion. Data are means+standard deviations for group
for WT and CD80/86−/− mice and single experiments for the other groups. WT—Frequency of virus-specific CD8 T cells is unaffected by lack of
CD80/86
Although the total number of CD8 T cells was unaltered in
CD80/86−/− mice following infection with MHV-68, it
seemed possible that the viral reactivation observed in lungs
of these mice reflected a reduction in the number of virus-
specific CD8 T cells. To address this point, we compared the
frequency of virus-specific CD8 T cells in the lungs and spleen
of CD80/86−/− and wild-type mice to determine whether
CD80 and CD86 were critical for the expansion and trafficking
of virus-specific CD8 T cells in vivo. CD8 T cells were dual-
stained with fluorochrome-conjugated anti-CD8 and MHC
Class I peptide tetramers H2Kbp56 and H2-Kd p79, which
bind to T cells that recognize two major MHV-68 epitopes.
Our data showed that there was no significant difference in thefected wild-type and CD80/86−/−mice. Cell numbers in the BAL or spleen were
ere prepared from the spleens of individual mice and viable cell counts were
s of 3–5 mice at each time-point and are derived from 2 independent experiments
wild type; CII−/− MHC Class II−/−.
Fig. 5. Frequency of virus-specific CD8 Tcells is unaffected by lack of CD80/86. BAL or spleen cells were collected at days 16 and 50 after infection, and stained with
PE-conjugated H-2Dbp56 or H-2Kbp79 MHC peptide tetramers and PerCP-conjugated monoclonal antibody to CD8. The resulting populations were analyzed by flow
cytometry using a lymphocyte gate. Data are mean percentages of lymphocytes positive for both CD8 and tetramer staining+standard deviations, groups of 3–5 mice
at each time-point and are derived from 2 independent experiments for WT and CD80/86−/− mice and single experiments for the other groups.
Fig. 4. Lymphocyte subsets in the BAL and spleens of MHV-68-infected wild-type and CD80/86−/−mice. BAL or spleen cells were collected at days 16 and 50 after
infection, and stained with PE or FITC-conjugated monoclonal antibodies. The resulting populations were analyzed by flow cytometry using a lymphocyte gate. Data
are means+standard deviations for groups of 3–5 mice at each time-point and are derived from 2 independent experiments for WT and CD80/86−/− mice and single
experiments for the other groups. TCR— T cell receptor.
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of wild-type and CD80/86−/− mice at either day 16 or day 50
after infection (Fig. 5). Thus CD80 and 86 do not appear to be
essential for MHV-68-specific CD8 T cell expansion or
trafficking to the lung.
CD80 and 86 are essential for the MHV-68-specific antibody
response
CD28-deficient mice show a significantly reduced antibody
response to MHV-68 which is ineffective in preventing viral
reactivation (Kim et al., 2002; Lee et al., 2002). To determine
whether this was also the case in CD80/86−/− mice, MHV-68-
specific serum antibody titers were determined 50 days after
infection. There was a drastic reduction in virus-specific
antibody titers in CD80/86−/− mice compared with those in
wild-type mice (P<0.0001). Levels of virus-specific antibody
were close to baseline in the CD80/86−/− mice, demonstrating
the critical role that these molecules play in antibody responses
(Fig. 6).
Discussion
Previous studies have shown that, while mice lacking CD4 T
cells, CD40 or CD40L can initially clear replicating MHV-68
from the lungs, long-term control is compromised and viral
reactivation is observed commencing 20–30 days after infection
(Brooks et al., 1999; Cardin et al., 1996; Lee et al., 2002;
Sarawar et al., 1997, 2001). Our previous studies showed that
viral control can be restored in CD4 T-cell-deficient mice by
agonistic antibodies to CD40 (Sarawar et al., 2001). This
appears to be mediated by CD8 T cells. A possible explanation
for these observations was that stimulation via CD40 upregu-
lates CD80 and 86 on dendritic cells enabling activation of CD8
T cells via CD28. However, our subsequent studies showed thatFig. 6. CD80 and 86 are essential for the MHV-68-specific antibody response.
Serum was collected from groups of 4 wild-type or CD80/86−/− mice 50 days
after infection with MHV-68. Virus-specific antibody responses were deter-
mined by ELISA. Data are expressed as mean A405+standard deviation relative
to a positive control serum sample (pooled from MHV-68-infected wild-type
mice). There was a highly statistically significant difference between the
antibody responses for the two groups (P<0.0001, Student's t test).neither CD28 nor its downstream signaling molecule PKCθ are
required for the long-term control of MHV-68 (Giannoni et al.,
2005; Kim et al., 2002; Lee et al., 2002). As CD28 is the only
known receptor for CD80/86 that mediates T cell activation,
these studies suggested that CD80/86 would not play an
essential role in the long-term control of MHV-68. However,
although the present study shows that CD80 and 86 are
dispensable for primary clearance of replicating virus, an
unexpected role for these molecules in the long-term control of
MHV-68 was revealed using CD80/86−/− mice. Our studies
with mice deficient in either CD80 or 86 alone showed that
these molecules play overlapping roles in the long-term control
of MHV-68.
There are two possible explanations for the disparity in the
requirement for CD28 and CD80/86 in the long-term control of
MHV-68: (1) an unexpected stimulatory function for CTLA4,
which has previously been shown to be a negative regulator of T
cell function, (2) the existence of a second, currently
unidentified stimulatory receptor for CD80/86. There is
evidence in the literature from other models supporting both
of these hypotheses. A recent paper (Schneider et al., 2005)
showed that CTLA4 engagement by CD80 upregulates
lymphocyte function-associated antigen-1 (LFA-1), which is
required for antigen-presenting cell function and T cell
migration, suggesting a positive regulatory role in T cell
function. However, a previous study by Sharpe and colleagues
(Mandelbrot et al., 2001) has demonstrated B7 (CD80/86)-
dependent T cell costimulation in a model of cardiac allograft
rejection in mice lacking both CD28 and CTLA4, suggesting
the presence of an alternative receptor. Further work will be
necessary to distinguish between these possible explanations for
the differential requirement for CD28 and CD80/86 in long-
term control of MHV-68.
Studies in other viral models have shown that CD80/86-
mediated costimulation is important for the immune response
to vesicular stomatitis virus (McAdam et al., 2000), herpes
simplex virus (Thebeau and Morrison, 2002) and influenza
(Liu et al., 1997; Lumsden et al., 2000), although no disparity
in the requirement for CD80/86 and CD28 was reported. Both
humoral and cell-mediated immunity was compromised by
lack of B7 costimulation in these viral models. In the present
study, there was no significant difference in the number or
subset distribution of lymphocytes in the spleens or lungs of
CD80/86−/− and wild-type mice. Furthermore, there was no
significant difference in the frequency of virus-specific CD8 T
cells in the lungs or spleen. This suggests that CD80/86 is not
required for the expansion of CD8 T cells or for lymphocyte
trafficking to the lungs. In contrast, serum antiviral antibody
titers were dramatically reduced in CD80/86−/− mice,
confirming previous findings in other models (Borriello et
al., 1997; McAdam et al., 2000; Thebeau and Morrison,
2003). However, MHV-68 reactivation is unlikely to result
solely from failure to mount a virus-specific antibody
response, as B-cell-deficient mice are able to maintain
effective long-term control of the virus (Usherwood et al.,
1996) and do not show viral reactivation in the lungs. Stewart
et al. showed that, once latency has been established, either B
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68 in the lungs (Stewart et al., 1998). However, the CD8 T
cells that develop in the absence of CD4 T cell help appear to
be compromised in their ability to mediate long-term control
of the virus (Cardin et al., 1996). The basis of this defect is
currently unknown since CTL activity, IFN-γ production and
the frequency of virus-specific CD8 T cells are not reduced
(Sarawar et al., 2001; Stevenson et al., 1998). Thus it seems
likely that viral reactivation that we observed in CD80/86−/−
mice reflects defects in both T cell and antibody-mediated
immunity.
In summary, our data show an unexpected disparity in the
requirement for CD80/86 and CD28 in the long-term control of
MHV-68. These data suggest that effective long-term control of
this virus may be mediated via a T cell activation pathway that
involves a previously unreported stimulatory function of
CTLA4 or the interaction of CD80/86 with a novel receptor.
Materials and methods
Mice
CD80−/−, CD86−/−, CD80/86−/− (double-deficient),
CD28−/− and wild-type C57BL/6 controls were purchased
from Jackson (Bar Harbor, Maine) Age- and sex-matched 8- to
15-week-old mice were used in all experiments. Mice were
housed under specific pathogen-free conditions in the Animal
Resource Center at TPIMS.
Viral infection and sampling
MHV-68 virus (Clone G2.4) (Blaskovic et al., 1980; Sunil-
Chandra et al., 1992a, 1992b) was propagated in BHK-21 cells
(ATCC CCL-10). Mice were anesthetized with Avertin (2,2,2
tribromoethanol) and infected intranasally with 105 PFU of the
virus in PBS. At various intervals after infection, the mice were
terminally anesthetized with Avertin and bled from the right
axilla or vena cava. The inflammatory cells infiltrating the lung
were harvested by bronchoalveolar lavage (BAL) via the
trachea and single cell suspensions were prepared from the
spleen. Following lavage, the lungs were removed and stored
frozen at −80 °C prior to virus titration.
Virus titration
Titers of replicating virus were determined by plaque assay
on NIH 3T3 cells (ATCC CRL1658) as described previously
(Cardin et al., 1996). Briefly, dilutions of stock virus,
homogenized mouse tissues or homogenized splenocytes were
adsorbed onto NIH 3T3 monolayers for 1 h at 37 °C and
overlaid with carboxymethyl cellulose (CMC). After 6 days, the
CMC overlay was removed, the monolayers fixed with 10%
formalin in PBS and stained with 1% Crystal Violet to facilitate
determination of the number of plaques. The detection limit of
this assay is 10 PFU/0.1 g lung tissue or 8 PFU/107 splenocytes
based on plaques recovered from homogenates of uninfected
tissues spiked with known amounts of virus.Infectious centers assay
Latent virus was assessed in splenocyte suspensions by an
infectious centers assay as previously described (Cardin et al.,
1996). Briefly, graded numbers of splenocytes from virus
infected wild-type or CD80/86−/− mice were plated on
monolayers of NIH 3T3 cells, incubated overnight at 37 °C
and the overlaid with CMC. Six days later plaques representing
viral reactivation from a single cell were counted after fixation
and staining as described above. No replicating virus was
detected in preparations of splenocytes disrupted by homo-
genization to prevent reactivation.
Flow cytometric analysis
Cells were stained with phycoerythrin (PE), fluorescein
(FITC) or PerCP-conjugated monoclonal antibodies as
previously described (Sarawar and Doherty, 1994). Anti-
bodies were purchased from B.D. PharMingen (San Diego,
CA), E-Biosciences (San Diego, CA) or Biolegend (San
Diego, CA). Isotype controls were included in each assay. In
some experiments, cells were also stained with PE-conjugated
MHC Class I peptide tetramers (H-2Kbp56 or H-2Dbp79) as
previously described (Stevenson et al., 1999). Tetramers were
obtained from the NIH tetramer facility (Atlanta, GA).
ELISA for virus-specific antibody
Serum antibody titers were determined by ELISA, as
described previously (Lee et al., 2000), using peroxidase-
labeled secondary reagents from Southern Biotechnology
(Birmingham, AL). Sera from uninfected mice and positive
control sera were included in the assay.
Statistical analysis
Data were analyzed with SigmaStat software (Jandel
Scientific, St. Rafael, CA) using Student's t test or the Mann–
Whitney rank sum test, depending on whether the data were
normally distributed.
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